| Open Document File Size: 1,06 MBShare Result on Facebook
Company AEs / CBC / ApoPharma Inc. / Cmax / RMP Risk Management Plan RR / Deferoxamine / DFO Treatment Groups / DFX deferasirox AE / Deferiprone ApoPharma Inc. / ITT / / Country United States / / Currency pence / / Event Product Issues / FDA Phase / / IndustryTerm deferoxamine / magnetic resonance imaging / dual energy x-ray / risk management / healthcare / food / / MedicalCondition CMR cardiac magnetic resonance HCV hepatitis C / PA pulmonary artery PK / Chronic transfusion therapy / transfusional siderosis / disease / transfusion-dependent thalassemia / Myelodysplastic syndrome / cardiac failure / iron overload / Neutropenia / Non Thalassemia Major / fatal agranulocytosis / liver fibrosis / Regulatory Activities TM thalassemia / Thalassemia Major / gastrointestinal hemorrhage / cardiac disease / sickle cell disease / liver cirrhosis / iron-induced cardiac disease / Thalassemia / renal and hepatic failure / virus COPD / certain other congenital anemias / agranulocytosis / / MedicalTreatment chelation therapy / / Organization Food and Drug Administration / European Medicines Agency / US Federal Reserve / FDA / EU European Union / / Person SQUID LVEF / / Position Hb / major UK United Kingdom MRI / Executive / forward / / Product Exjade / Desferal / CK-7 / Ferriprox® (deferiprone) / tomography IND Investigational New Drug / LA36 / Inadequate chelation / Meeting date / previous chelation therapy / / Technology Pharmacokinetics / single nucleotide polymorphism / x-ray / magnetic resonance imaging / tomography / SNP / Pharmacodynamics / MRI / /
SocialTag |
oncologic drugs advisory committee briefing document sep[removed]